Cargando…

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway

BACKGROUND: Genome-wide association studies (GWAS) represent the current frontier in pharmacogenomics. Thousands of subjects of Caucasian ancestry have been included in previous GWAS investigating antidepressant response. GWAS focused on this phenotype are lacking in Asian populations. METHODS: A sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocchi, Enrico, Fabbri, Chiara, Han, Changsu, Lee, Soo-Jung, Patkar, Ashwin A., Masand, Prakash S., Pae, Chi-Un, Serretti, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836090/ https://www.ncbi.nlm.nih.gov/pubmed/27091189 http://dx.doi.org/10.1186/s12888-016-0813-x

Ejemplares similares

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
por: Wang, Sheng-Min, et al.
Publicado: (2018)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
por: Porcelli, Stefano, et al.
Publicado: (2015)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008)

Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples
por: Porcelli, Stefano, et al.
Publicado: (2016)

ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
por: Calabrò, Marco, et al.
Publicado: (2020)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder
por: Yun, Dong-Hwan, et al.
Publicado: (2008)

No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression
por: Serretti, Alessandro, et al.
Publicado: (2013)

Clinical specificity profile for novel rapid acting antidepressant drugs
por: Scala, Mauro, et al.
Publicado: (2023)

Pain and Depression: A Neurobiological Perspective of Their Relationship
por: Han, Changsu, et al.
Publicado: (2015)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders
por: Jeon, Sang Won, et al.
Publicado: (2017)

A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State
por: Patkar, Ashwin, et al.
Publicado: (2012)

Pharmacogenetics of antidepressant response: An update
por: Drago, Antonio, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_r7ikfmm651obbinoj0od1d1mhn